On November 4, 2026, the Social Security Institution (Sosyal Güvenlik Kurumu, SGK) published Announcement 2026/43 (Duyuru 2026/43, Bedeli Ödenecek İlaçlar Listesinde Yapılan Düzenlemeler Hakkında Duyuru 2026/43). The arrangements, made under article 12 of the Pharmaceutical Reimbursement Regulation and SUT article 4.4.1, enter into force on November 6, 2026.
Marketing authorisation holders of THERMONIDYN, VOTRYXE, IMBRUVICA, REVLIMID and REXULTI placed on the Turkish reimbursed market, Turkish pharmaceutical wholesalers supplying those EK-4/A packs, community and hospital pharmacies in Turkey that bill SGK, and suppliers of disease-specific medical foods on EK-4/B, including RENASTEP, must update SGK billing, barcodes and reimbursement status by November 6, 2026, so THERMONIDYN and VOTRYXE are payable from that date, amended packs including IMBRUVICA, REVLIMID, REXULTI and ADELEKS use the current barcode, isotonic sodium chloride 500 ml and lactated Ringer 1000 ml are no longer billed from November 6, 2026, and RENASTEP is billed from November 4, 2026, or a medicine or medical food billed outside its updated EK-4/A or EK-4/B status is not paid by SGK.
What does Announcement 2026/43 change on the lists?
The Bedeli Ödenecek İlaçlar Listesi (List of Reimbursable Pharmaceuticals, annex EK-4/A) is the SGK list of medicines whose cost is paid under article 12 of the Social Security Institution Pharmaceutical Reimbursement Regulation and article 4.4.1 of the SUT (Sağlık Uygulama Tebliği).
Annex EK-1 adds THERMONIDYN 1% + 0.025% gel (A20495, barcode 8680186490721, equivalent group E247F) and VOTRYXE 75 mcg tablets, pack of 50 (A20496, barcode 8699511010404, group E509C, price-protected), both with a list-entry date of November 6, 2026. Annex EK-2 amends barcodes and discount status. Annex EK-3 sets a passivation date of November 6, 2026 on three infusions. Annex EK-4 amends RENASTEP on EK-4/B, and the spreadsheet states that this starred line takes effect on November 4, 2026. The SGK announcement and Duyuru.pdf are the official texts.
| Annex | Product | Barcode | Change |
|---|---|---|---|
| EK-1 | THERMONIDYN gel | 8680186490721 | Added, equivalent, November 6, 2026 |
| EK-1 | VOTRYXE 75 mcg, 50 tablets | 8699511010404 | Added, price-protected, November 6, 2026 |
| EK-2 | ADELEKS 4 mg, 20 tablets | 8685119899008 | Replaces 8699541014304 |
| EK-2 | ADELEKS 4 mg/2 ml, 6 ampoules | 8685119899022 | Replaces 8699541751605 |
| EK-2 | ADELEKS 8 mg, 14 tablets | 8685119899015 | Replaces 8699541015226 |
| EK-2 | IMBRUVICA 420 mg, 30 tablets | 8699593095603 | Reference, A19638 |
| EK-2 | IMBRUVICA 560 mg, 30 tablets | 8699593095610 | Reference, A19639 |
| EK-2 | REVLIMID 25 mg, 21 capsules | 8699726151084 | Reference, special discount 0.05 |
| EK-2 | REXULTI 0.5 mg, 28 tablets | 8680683090028 | Reference, group E1003A |
| EK-2 | RECTUS enema 135 ml | 8684396040585 | Replaces 8681812046206 |
| EK-2 | RECTUS enema 210 ml | 8684396040592 | Replaces 8681812046213 |
| EK-2 | TANFLEX PLUS gargle 200 ml | 8699514640097 | Replaces 8699772646824 |
| EK-3 | Isotonic sodium chloride 500 ml, no set | 8699508690275 | Passivated November 6, 2026 |
| EK-3 | Lactated Ringer 1000 ml, with set | 8699508690152 | Passivated November 6, 2026 |
| EK-3 | Lactated Ringer 1000 ml, no set | 8699508690398 | Passivated November 6, 2026 |
| EK-4/B | RENASTEP 24 x 125 ml | 8690632710372 | In force November 4, 2026 |
Who must update billing before November 6, 2026?
Holders of the marketing authorisations for these EK-4/A packs, wholesalers who supply them in Turkey, and community and hospital pharmacies that bill SGK must load the annex. Suppliers of EK-4/B medical foods, including RENASTEP, do the same for that line.
In November 2026, Obsidian tracks 9 regulatory texts (in force, amended or in preparation) for the Life Sciences & MedTech industry in Turkey.
RENASTEP is coded as a medical food, entered the list on October 24, 2026, starts band-account tracking on November 4, 2026, and the distribution document is notified by March 24, 2027.
What must be in the claim file by November 6, 2026?
The claim file must use the current barcode in the November 4, 2026 spreadsheet and must not claim a passivated infusion from November 6, 2026.
- Mark THERMONIDYN gel (8680186490721) and VOTRYXE 75 mcg (8699511010404) payable from November 6, 2026.
- Replace the three ADELEKS barcodes, both RECTUS barcodes and the TANFLEX PLUS barcode with the current numbers in the table.
- Bill IMBRUVICA 420 mg and 560 mg, REVLIMID 25 mg and REXULTI 0.5 mg on the EK-2 barcodes.
- Stop billing isotonic sodium chloride 500 ml without set and both lactated Ringer 1000 ml lines from November 6, 2026.
- Bill RENASTEP (8690632710372) from November 4, 2026, and keep March 24, 2027 for the distribution-document notice.
Continuous, per-jurisdiction monitoring surfaces an SGK list amendment of this kind the moment the announcement is published.
What does SGK refuse if the annex is ignored?
A medicine or medical food billed outside its updated EK-4/A or EK-4/B status is not paid by SGK. Announcement 2026/43 states no separate fine. Non-payment is the effect of a passivated line, a superseded barcode, or a product that is not yet payable.
Match each public number to the article 12 spreadsheet before claims go out.
Check whether your packs sit on EK-1, EK-2, EK-3 or EK-4, load the current barcode, and brief pharmacy billing and market access before November 6, 2026. RENASTEP follows November 4, 2026.
